ViralVax Lab
banner
viralvaxlab.bsky.social
ViralVax Lab
@viralvaxlab.bsky.social
Viral vaccine and immunology lab at the Peter Doherty Institute, University of Melbourne.
We are excited to share our paper describing neutralising monoclonal antibodies against human coronavirus NL63, an alphacoronavirus that uses the same ACE2 receptor as SARS-CoV and SARS-CoV-2, but generally only causes mild respiratory illness. www.nature.com/articles/s44...
Potent neutralising monoclonal antibodies targeting the spike of NL63 coronavirus - npj Viruses
npj Viruses - Potent neutralising monoclonal antibodies targeting the spike of NL63 coronavirus
www.nature.com
May 1, 2025 at 4:06 AM
Reposted by ViralVax Lab
New research from @thedohertyinst.bsky.social suggests that receiving multiple doses of a vaccine in the same limb leads to faster antibody development, an important strategy for providing #immunity quickly during a pandemic or disease #outbreak. #ReadTheJI #immunology

ow.ly/c28N50VeRGR
Modulation of germinal center and antibody dynamics via ipsilateral versus contralateral immunization against SARS-CoV-2
Abstract. Human clinical trials have reported immunological outcomes can differ between ipsilateral (same side) and contralateral (alternate sides) prime-b
ow.ly
March 10, 2025 at 3:09 PM
1/ Hot off the press in @jimmunol.bsky.social. We investigated how same side (ipsilateral) vs alternate side (contralateral) prime-boost vaccination impacts germinal center (GC) dynamics & antibody responses against SARS-CoV-2 spike in mice.💉🦠#immunology #vaccines @thedohertyinst.bsky.social
March 11, 2025 at 5:59 AM
Check out the latest from @skentskent.bsky.social and team - how does co-administration of influenza and COVID-19 vaccines affect immunity? Congrats to Wen Shi Lee, Kevin Selva and Jen Audsley on a great study and collaboration between the ViralVax and Chung labs!

insight.jci.org/articles/vie...
Influenza vaccination is equivalently immunogenic if given in same or opposite arms as the SARS-CoV-2 vaccine, but it may be preferable to administer the SARS-CoV-2 vaccine at a different site to influenza vaccines
insight.jci.org/articles/vie...
@jci-insight.bsky.social
January 10, 2025 at 12:24 AM